000282680 001__ 282680
000282680 005__ 20240229162357.0
000282680 0247_ $$2doi$$a10.21037/tcr-22-2651
000282680 0247_ $$2ISSN$$a2218-676X
000282680 0247_ $$2ISSN$$a2219-6803
000282680 037__ $$aDKFZ-2023-01826
000282680 041__ $$aEnglish
000282680 082__ $$a610
000282680 1001_ $$aWyrich, Martine$$b0
000282680 245__ $$aInduction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
000282680 260__ $$aShatin$$bAME Publishing Company$$c2023
000282680 3367_ $$2DRIVER$$aarticle
000282680 3367_ $$2DataCite$$aOutput Types/Journal article
000282680 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694173759_27136
000282680 3367_ $$2BibTeX$$aARTICLE
000282680 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282680 3367_ $$00$$2EndNote$$aJournal Article
000282680 520__ $$aBackground: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin in combination with pemetrexed offers the best options. Detoxification of heavy metals in the cell by metallothioneins (MT) is associated with early failure to platin-based chemotherapy. The induction of MTs gene expression or its enzyme results in saturation by exposure to metal ions such as zinc or cadmium. Its therapeutically effect is still not analyzed in depth. Methods: In our study, we investigated three MPM cell lines and one fibroblast cell line in the course of cisplatin treatment and supplementation of zinc. Cell state analyses via an enzyme-activity based assay were performed. With this, we were able to analyze apoptosis, necrosis and viability of cells. Additionally, we tested treated cells for changes in metallothionein IIA (MT2A) expression by using quantitative realtime polymerase chain reaction. Results: Zinc supplementation induces gene expression of MT2A. Overall, a zinc dose-dependent induction of apoptosis under platin-based treatment could be observed. This effect could be verified in all analyzed cell lines in varying intensity. Conclusions: MT expression is induced by zinc in a dose-dependent manner and inhibits a successful cisplatin therapy. Therefore, heavy metal exposure during cisplatin therapy, e.g., via cigarette smoke, might be an important factor. This should be considered in further therapeutic approaches.
000282680 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000282680 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000282680 7001_ $$aOhlig, Henning$$b1
000282680 7001_ $$0P:(DE-HGF)0$$aWessolly, Michael$$b2
000282680 7001_ $$aMairinger, Elena$$b3
000282680 7001_ $$aSteinborn, Julia$$b4
000282680 7001_ $$aBrcic, Luka$$b5
000282680 7001_ $$aHegedus, Balazs$$b6
000282680 7001_ $$aHager, Thomas$$b7
000282680 7001_ $$aGreimelmaier, Kristina$$b8
000282680 7001_ $$aWohlschlaeger, Jeremias$$b9
000282680 7001_ $$0P:(DE-He78)b95d3d97744eba350556aa1d025aa300$$aMairinger, Fabian$$b10$$udkfz
000282680 7001_ $$0P:(DE-HGF)0$$aBorchert, Sabrina$$b11
000282680 773__ $$0PERI:(DE-600)2901601-0$$a10.21037/tcr-22-2651$$gVol. 12, no. 8, p. 1929 - 1936$$n8$$p1929 - 1936$$tTranslational cancer research$$v12$$x2218-676X$$y2023
000282680 909CO $$ooai:inrepo02.dkfz.de:282680$$pVDB
000282680 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000282680 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b95d3d97744eba350556aa1d025aa300$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000282680 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000282680 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000282680 9141_ $$y2023
000282680 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000282680 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000282680 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL CANCER RES : 2022$$d2023-10-27
000282680 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000282680 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000282680 980__ $$ajournal
000282680 980__ $$aVDB
000282680 980__ $$aI:(DE-He78)ED01-20160331
000282680 980__ $$aUNRESTRICTED